Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Virginia Jethro

Physician Assistant, Medical Cary, NC Physician Assistant

NPI 1114988292 CMS profile 10992579

1110 Se Cary Pkwy, Suite 206, Cary, NC 27518

Open in the dashboard

General payments

$212,893

1,149 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Virginia Jethro of Cary, NC is reported in the CMS Open Payments database as having received $212,893 across 1,149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,645 242
2024 General $29,092 227
2023 General $54,258 288
2022 General $29,590 226
2021 General $48,309 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Virginia Jethro
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Virginia Jethro were reported at $51,645. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Virginia Jethro Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $48,309 $156 $41–$563 $132
2022 $29,590 $185 $55–$649 $149
2023 $54,258 $199 $58–$717 $160
2024 $29,092 $206 $62–$740 $164
2025 $51,645 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $175,692 443 payments
  2. Axsome Therapeutics, Inc. $16,790 41 payments
  3. Pfizer Inc. $4,479 41 payments
  4. UCB, Inc. $2,219 96 payments
  5. Lundbeck LLC $2,162 62 payments
  6. Allergan Inc. $1,290 4 payments
  7. Amgen Inc. $956 42 payments
  8. Biogen, Inc. $740 21 payments
  9. Eisai Inc. $678 32 payments
  10. Novartis Pharmaceuticals Corporation $614 36 payments
  11. Other $7,273 331 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $166,128 114 payments
  2. Food and Beverage $19,442 944 payments
  3. Honoraria $13,650 8 payments
  4. Travel and Lodging $10,879 74 payments
  5. Consulting Fee $2,775 7 payments
  6. Education $19 2 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $145,609 341 payments
  2. QULIPTA $86,850 244 payments
  3. Symbravo $16,777 40 payments
  4. NURTEC ODT Pain $4,393 37 payments
  5. VYEPTI $2,065 56 payments
  6. Briviact $1,147 56 payments
  7. AIMOVIG $787 35 payments
  8. NURTEC ODT Primary Care $730 28 payments
  9. Fintepla $621 23 payments
  10. BRIUMVI $604 17 payments
  11. Other $9,936 481 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,166

Median for Physician Assistant: 241

Drug cost

$172,443

Median for Physician Assistant: $4,110

Branded share of claims

25%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 29 $47,125
Nurtec Odt Rimegepant Sulfate Brand 24 $24,453
Aimovig Autoinjector Erenumab-Aooe Brand 32 $22,862
Ajovy Autoinjector Fremanezumab-Vfrm Brand 21 $17,561
Emgality Pen Galcanezumab-Gnlm Brand 17 $16,443
Qulipta Atogepant Brand 15 $15,532
Rivastigmine Generic 23 $4,466
Gabapentin Generic 166 $3,541
Memantine Hcl Generic 94 $2,720
Sumatriptan Succinate Generic 16 $2,304

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$31,057

Medicare's payments for the services billed

Medicare patients

307

Average age 74

Services billed

651

180 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 36%
Depression 32%
Ischemic heart disease 29%
Chronic kidney disease 29%
Alzheimer's or dementia 20%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$14,223 29 —
QULIPTA
$10,678 15 —
VYEPTI
$1,262 — —
Briviact
$493 — —
Leqembi
$327 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record